The categorization of cancer treatments is becoming more complex as we move into the era of molecular profiling. In a detailed Keytruda Market Segment report, we see a clear distinction between monotherapy applications and combination therapy applications. While monotherapy was the standard in the early days of PD-1 inhibitors, the current shift is toward using pembrolizumab as a "backbone" therapy, where it is paired with other drugs to enhance the immune response.

This segmentation also extends to the clinical stage of the cancer. The "adjuvant" segment—treatment given after the primary tumor is removed—is one of the fastest-growing areas. By treating patients when there is minimal residual disease, the goal is to achieve a functional cure. This shift from late-stage palliative care to early-stage curative-intent therapy is fundamentally changing the market's long-term outlook and patient survival expectations.

FAQ:

• Q: What is the difference between adjuvant and neoadjuvant therapy?

• A: Neoadjuvant is given before surgery to shrink tumors; adjuvant is given after surgery to kill any remaining cells.

Related Reports: